Glenmark Pharmaceuticals Ltd. Share Price

Glenmark Pharmaceuticals Launches Pump Packs

MACRO DATA--> UPDATE THAT BENEFIT THIS SECTORS STOCKS!

India’s foreign exchange reserves have witnessed another sharp decline. For the week ended September 25, 2026, India’s forex reserves fell by $18.34 billion to around $747.56 billion. This was the third consecutive weekly decline, with reserves falling by more than $38 billion over three weeks from the record high of around $785.71 billion reached earlier in September. But the bigger question for investors is: What does falling forex reserves mean for the Rupee and Indian stocks? Why Did Forex Reserves Fall? The biggest decline came from Foreign Currency Assets (FCAs). Foreign Currency Assets ↓ $15.57 billion to around $615.41 billion Gold reserves also declined by around $2.59 billion to approximately $108.70 billion. The fall comes amid pressure on the Indian Rupee, with the RBI intervening in the foreign exchange market to manage excessive currency volatility. ---->🇮🇳 What Does This Mean for the Rupee? The important transmission mechanism is: Forex Pressure → Rupee Pressure → USD/INR Moves Higher If the Rupee weakens against the US Dollar, companies that earn a significant portion of their revenue in dollars can benefit when those revenues are converted back into Rupees. This creates an important distinction: Weak Rupee = Negative for Importers --->IT AND PHARMA Sector Could Benefit

FPIs pour Rs 15,800 crore into pharma since July

Foreign portfolio investors invested ₹15,800 crore into Indian pharmaceutical shares between July and the first half of September. Despite this sector-wide inflow, IPCA Laboratories Limited

Glenmark Receives US FDA Inspection Report for Goa Facility

Glenmark Pharma: Can the Uptrend Regain Momentum?

Glenmark Pharma closed at ₹2,410, up 1.61%, after finding support around the ₹2,350–₹2,400 zone. The key number to watch is ₹2,405, where the 20-day EMA is currently placed. Technically, the stock remains in a broader uptrend. Price is trading above the 20 EMA (₹2,405), 50 EMA (₹2,345), 100 SMA (₹2,293) and 200 SMA (₹2,175), keeping the medium- to long-term structure positive. However, the stock has recently cooled off after approaching the ₹2,500–₹2,535 zone, which is an important resistance area. The RSI is at 53.06, indicating that momentum has moderated from overbought levels but has not entered a weak zone. This leaves room for momentum to rebuild if buyers regain control. The MACD is showing some loss of short-term momentum, with the histogram turning negative. This suggests that the stock may need some consolidation before attempting another sustained upward move. From a fundamental perspective, Glenmark reported strong Q1 FY27 numbers, with consolidated revenue rising 23.1% YoY to ₹4,018 crore and net profit reaching ₹483 crore. What to watch next: ₹2,405 is the immediate support. Holding above this level can keep the recovery structure intact, while a sustained move above ₹2,450–₹2,500 would bring the recent high zone back into focus. A close below ₹2,405 may increase the probability of a deeper correction towards ₹2,345. My View: The larger trend remains positive, but short-term momentum needs confirmation. Traders should watch the ₹2,405 support and ₹2,500 resistance closely before taking a directional view. Disclosure: The views expressed are based on technical and publicly available fundamental information and are for educational purposes only. Please consult your financial advisor before making any investment decision.

Expands Global Respiratory Innovation Footprint

Cdoe BSE: 532296 NSE: